A Pfizer Inc

May 2012
MondayMorning;5/21/2012, Vol. 20 Issue 21, p1
The article informs that Xalkori drug from Pfizer Inc. has been found eradicated signs of malignancy in some kids with rare tumors of the nerves, blood and soft tissue. According to Michael Link, a Stanford University pediatric cancer specialist and president of the American Society of Clinical Oncology, it is a glimpse of the new paradigm of cancer drug development.


Related Articles

  • The War on Cancer: New Drugs for Advanced Kidney Cancer -- Do They Work? Moss, Ralph W. // Townsend Letter;Jan2007, Issue 282, p36 

    The article discusses the development of the new drug Sutent from Pfizer Inc. which is as a treatment for advanced kidney cancer in the U.S. The author talks about the approval by the European Union following the drug's approval in the U.S. Moreover, he focuses on the efficacy of the drug as...

  • Pfizer: development setbacks cast doubt over Sutent.  // PharmaWatch: Cancer;Aug2009, Vol. 8 Issue 8, p4 

    In this article the author discusses the termination of the Phase III study conducted by Pfizer Inc. in the U.S. in 2009 regarding the use of Sutent as treatment of metastatic colorectal cancer. The termination of the study is indicated as due to the failure of the combination of Sutent and...

  • HELP And HOPE. DUNKIN, MARY ANNE // Georgia Trend;Apr2014, Vol. 29 Issue 8, p24 

    The article focuses on the prominence of Georgia for treatment of cancer in children. Among the key topics that were discussed include the participation of pediatric oncologist in Phase III clinical trials which are studies involving drugs for cancer, development of new cancer therapies by...

  • Planning Beyond the Petri Dish. Looney, William // Pharmaceutical Executive;Jul2011, Vol. 31 Issue 7, p38 

    The article highlights the development of crizotinib, a new targeted therapy from Pfizer Inc., that blocks progression of non-small-cell lung cancer (NSCLC) in the U.S. It notes that the development has exemplified the success of the combined art, science and unforeseen risks. Senior director...

  • Pfizer Abandons Heart Drug Development. Faloon, William // Life Extension;Nov2009, Vol. 15 Issue 11, p1 

    The article reports on the announcement given by Pfizer Inc., the largest drug company in the world, that it will no longer develop drugs that prevent or treat atherosclerotic heart disease. According to the company, they wanted to concentrate new drug research on more profitable areas like...

  • Pfizer Phase III Failure Hints at ADC Shortcomings. Powers, Marie // BioWorld Today;5/22/2013, Vol. 24 Issue 98, p1 

    The article reports that pharmaceutical company Pfizer Inc. will discontinue the Phase III trial of inotuzumab ozogamicin (NHL), an antibody conjugate (ADC), in treating non-Hodgkin's lymphoma (NHL). It states that the decision to end the drug development arises because NHL shows no success...

  • PFIZER INC.  // MondayMorning;6/25/2012, Vol. 20 Issue 25, p1 

    The article informs that the lung-cancer drug Xalkori from Pfizer Inc. has helped the patients who had previously been treated for the disease. The company mentioned that Xalkori worked better than two older cancer drugs in the late-stage clinical trial. It adds that the U.S. Food and Drug...

  • Pfizer: Aromasin patent could dampen its potential.  // PharmaWatch: Cancer;May 2004, Vol. 3 Issue 5, p23 

    Profiles pharmaceutical company Pfizer Inc. Company's release of positive study data for the metastatic breast cancer treatment Aromasin; Description of the company's business operations; Sales and marketing capabilities; Weaknesses; Growth opportunities.

  • New Product Briefs.  // Journal of Oncology Management;Jan/Feb2005, Vol. 14 Issue 1, p22 

    Reports on developments concerning drugs for the treatment of breast cancer. Pfizer's submission of a supplemental new drug application to the United States Food and Drug Administration seeking approval for Aromasin (exemestane tablets) in the adjuvant treatment of postmenopausal women with...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics